Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Venezuela Pharmaceuticals And Healthcare
Industry SWOT Analysis — 6
Venezuela Political SWOT
Analysis — 7
Venezuela Economic SWOT
Analysis — 8
Venezuela Business Environment SWOT
Analysis — 8
Pharmaceutical Business Environment
Ratings — 9
Table: Pharmaceutical Business Environment
Ratings — 9
Limits of Potential
Returns — 9
Risks to Realisation of
Returns — 10
Regulatory Regime — 13
Intellectual Property Environment — 13
International
Collaboration — 16
Counterfeit
Drugs — 17
Pricing And
Reimbursement — 18
Other Regulatory
Issues — 20
Industry Developments — 21
Epidemiology — 21
Healthcare
Sector — 23
Hospital Sector — 24
Private Healthcare Sector — 25
Regional Healthcare
Collaboration — 25
Pharmaceutical
Sector — 26
Company Activity — 29
OTC
Medicines — 29
Pharmacy Sector — 30
Medical Devices — 32
Industry Forecast
Scenario — 33
Overall Market
Forecast — 33
Table: Venezuela – Drug Expenditure
Indicators, 2003-2013 — 34
Key Growth Factors –
Industry — 35
Table: Venezuela – Health Expenditure
Indicators, 2003-2013 — 36
Key Growth Factors –
Macroeconomic — 37
Economic
Activity — 37
Table: Venezuela - Economic Activity,
2005-2013 — 39
Prescription Drug Market
Forecast — 40
Table: Venezuela – Prescription Market
Indicators, 2003-2013 (VEBmn unless otherwise stated) — 41
Patented Market Forecast — 42
Table: Venezuela –
Patented Market Indicators, 2003-2013 — 43
Generics Market
Forecast — 43
Table: Venezuela - Generics Market
Indicators, 2003-2013 — 45
OTC Market
Forecast — 46
Table: Venezuela – OTC Market
Indicators, 2003-2013 (VEBmn unless otherwise stated) — 47
Import/Export Forecasts — 48
Table: Venezuela –
Import/Export Indicators, 2003-2013 (US$mn) — 49
Medical
Devices Forecasts — 50
Table: Venezuela’s Medical
Device Market, 2006-2013 (US$mn unless otherwise
stated) — 51
Other Healthcare Data
Forecasts — 52
Table: Venezuela - Other Healthcare Data,
2003-2013 — 52
Key Risks to BMI’s Forecast
Scenario — 53
Competitive
Landscape — 54
Company Profiles — 55
Leading Multinationals — 55
Pfizer — 55
Sanofi-Aventis — 57
GlaxoSmithKline — 58
Boehringer
Inglelheim — 60
Novartis — 62
Merck &
Co — 64
Indigenous Company
Profiles — 66
Grupo Farma — 66
Elmor — 68
Strides Latina
(Sumifarma) — 70
Calox
International — 72
Country Snapshot: Venezuela Demographic
Data — 73
Section 1: Population — 73
Table: Demographic Indicators, 2005-2030 — 73
Table:
Rural/Urban Breakdown, 2005-2030 — 74
Section 2: Education
And Healthcare — 74
Table: Education,
2002-2005 — 74
Table: Vital Statistics,
2005-2030 — 74
Section 3: Labour Market And Spending
Power — 75
Table: Employment Indicators,
2001-2006 — 75
Table: Consumer Expenditure, 2000-2012
(US$) — 75
How We Generate Our Pharmaceutical Industry
Forecasts — 76
Pharmaceutical Business Environment Ratings
Methodology — 77
Ratings Overview — 77
Table: Pharmaceutical Business Environment Indicators — 78
Weighting — 79
Table: Weighting Of
Components — 79
Sources — 79
| 
View Cart
